New Rules for Using Social Media in Marketing FDA Regulated Products

Date: March 19, 2025
Duration: 60 Minutes
Time: 12 PM EST

Social media offers an excellent opportunity for a company to get the word out about its drugs, biologics, medical devices and diagnostic kits. However, FDA regulated products need to follow strict information control; any information distributed to consumers must be approved by FDA. This is hard with social media outlets where information can quickly get out of hand and lead to violation of FDA regulations, and possible penalties on the manufacturers.

The FDA recently held hearings addressing drug companies’ use of social media and other online platforms to advertise. FDA also released a guidance document about manufacturers’ obligation regarding off-label information available about their products. Another guidance document about use of social media in marketing is expected soon. In addition, FDA issued several letters to manufacturers indicating the rules for using social media.

But there is still much confusion among FDA regulated companies how to use social media for marketing effectively and still be compliant with regulations. How can medical device, pharmaceutical and other FDA regulated industries use social media channels like Facebook, Twitter, YouTube and LinkedIn to get their message out in a way that is compliant with advertising and promotion regulations found in the Food Drug & Cosmetic Act? This presentation will present ways to use social media that are compliant with FDA regulations. Practical regulatory strategies will be suggested to ensure compliance and balanced social media activity.

 

Areas Covered in the Session:

  1. How Direct-to-consumer-advertising (“DTCA”) guidance impacts the use of social media.
  2. Common ways companies are currently using social media.
  3. FDA advertising and promotion issues related to social media.
  4. A structure for analysis of responsibility for promotion in social media.
  5. Handling unsolicited requests for off-label information
  6. Recent trends in FDA enforcement actions involving social media.
  7. Recent discussions about social media in marketing of FDA-regulated products. 

Why should you attend:

The seminar will discuss the do’s and don’ts for using social media in marketing FDA-regulated products. Common issues, misconceptions, perceptions, and possible solutions will be discussed. In a social media rich environment, manufacturers cannot avoid information dissemination via social media, hence it is prudent to familiarize with the current processes and plan for developments expected in the near future.

Learning Objectives:

At the end of the seminar, the attendees will be familiar with the following:

  1. Recent FDA guidance on controlling dissemination of information via social media
  2. Common practices for using social media such as Facebook, YouTube, and Twitter
  3. Meeting with FDA to discuss social media submissions
  4. Trends in FDA review of social media information
  5. Do’s and Don’ts for managing social media for marketing your product

Who will benefit: 

The following individuals or disciplines will benefit from attending this Webinar:

  1. Clinical project managers
  2. Clinical research associates
  3. Clinical coordinators
  4. Principle investigators
  5. Compliance Managers
  6. Regulatory Vice Presidents, Directors and Managers
  7. Attorneys – In-house or Outside Counsel
  8. Senior executives of pharmaceutical and device firms

Speaker: Mukesh Kumar

​PhD, RAC | CEO, FDAMap

For more info, fill the box below. We will contact you within 24 hrs.

Webinar Fee

Prices are in US Dollars.
The registration fee includes: The live webinar & all related course materials.

Terms & Conditions to register for the Webinar

Your Registration for the workshop is subject to following terms and conditions. If you need any clarification before registering for this webinar please email us at info@fdamap.com

Payment

We accept credit card, debit card, and PayPal. 

Cancellations & Substitutions:

Written cancellations through fax or email (from the person who has registered for this conference) received at least 5 business days prior to the start date of the event will receive a refund — less a $30 administration fee. No cancellations will be accepted — nor refunds issued — within 5 business days before the start date of the event. You may however, choose to substitute the webinar for which you are registered with some other webinar in the future.

On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($30) will be transferred to any future FDA Map event and a credit note will be issued. No-shows will be charged the full amount.

Webinar material will be uploaded on the website 24 hours before the scheduled date of the webinar. In case it is not available on the website due to some technical issues, we will email the material a few hours before the start of the webinar.

In the event FDA Map cancels the webinar, FDA Map will issue a full refund to all the registrants for that webinar. Some topics and speakers may be subject to change without notice.

For any information on the training agenda and logistics, please call +1 410-501-5777 or email: info@fdamap.com